MedPath

Cross Cultural Validation of the Italian Version of the Clinical Assessment of Dysphagia in Neurodegeneration

Recruiting
Conditions
Swallowing Disorder
Dysphagia
Neuro-Degenerative Disease
Interventions
Other: Administration of Clinical Assessment of Dysphagia in Neurodegeneration (CADN)
Registration Number
NCT05733494
Lead Sponsor
Istituti Clinici Scientifici Maugeri SpA
Brief Summary

The English version of the "Clinical Assessment of Dysphagia in Neurodegeneration" (CADN), represents a rapid and valid clinical assessment tool for dysphagia in neurodegenerative population.

Currently, there is no validated tool in Italian specific for the clinical assessment of dysphagia in neurodegenerative disease with strong psychometric characteristics.

The present study aims to translate and validate the Italian version of CADN in neurodegenerative population. Psychometric properties will be measured.

Detailed Description

Most of patients with a neurodegenerative disease will develop swallowing impairments (dysphagia) during their disease progression (up to 80%- 100% in Parkinson disease and Amyotrophic Lateral Sclerosis).

Dysphagia is associated with serious clinical complications, particularly regarding loss of life quality, insufficient medication intake, malnutrition, dehydration, and aspiration with subsequent pneumonia, which is the leading cause of death in this population.

Early detection and measurement of dysphagia trough validated and standardized procedures plays a fundamental role in the clinical practice. Clinical assessment by a speech language pathologist (SLP) can provide early identification of dysphagia and its severity and direct clinical decision making.

The English version of the "Clinical Assessment of Dysphagia in Neurodegeneration" (CADN), represents a rapid and valid clinical assessment tool for dysphagia in neurodegenerative population.

Currently, there is no validated tool in Italian specific for the clinical assessment of dysphagia in neurodegenerative disease with strong psychometric characteristics.

The present study aims to translate and validate the Italian version of CADN in neurodegenerative population.

The study will be carried out in two phases:

1. Forward and back translation

2. Validation process

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
101
Inclusion Criteria
  • diagnosis of neurodegenerative disease according to the respective consensus criteria
  • >18 years old
  • able to provide informed consent
  • able to follow simple instructions
  • capable of sitting upright for anamnesis and examination for at least 20 min (in chair or wheelchair)
Exclusion Criteria
  • history of stroke
  • surgery to the head or neck
  • radiotherapy in the last 12 months
  • dysphagia resulting from other known causes

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients with neurodegenerative diseaseAdministration of Clinical Assessment of Dysphagia in Neurodegeneration (CADN)Patients with neurodegenerative disease
Primary Outcome Measures
NameTimeMethod
Clinical Assessment of Dysphagia in Neurodegeneration (CADN)at 24 hours from enrolment

Clinical assessment tool administrated by a Speech Language Pathologist. The CADN is composed by a clinical case history and a consumption part for a total of 11 item. Severity scores for each item range from 0 (no impairment) to 4 (severe impairment).

Secondary Outcome Measures
NameTimeMethod
Fiberoptic Endoscopic Evaluation of Swallowing (FEES)At the enrolment

Instrumental examination, gold standard for the assessment of dysphagia.

Trial Locations

Locations (1)

Istituti Clinici Scientifici Maugeri

🇮🇹

Milan, Milano, Italy

© Copyright 2025. All Rights Reserved by MedPath